Trinity Biotech Receives Early Approval from the World Health Organization to Begin Offshore Manufacturing of TrinScreen HIV & Uni-Gold HIV

Core Insights - Trinity Biotech plc has announced an important update regarding its Comprehensive Transformation Plan, specifically the transfer of manufacturing for TrinScreen HIV and Uni-Gold HIV to a lower-cost offshore partner [1][2] - The company received earlier than expected approval from the World Health Organization (WHO) for the later-stage manufacturing process at the outsourced facility, which is a key milestone in the transformation plan [1][2] Company Overview - Trinity Biotech is a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors [4] - The company develops, acquires, manufactures, and markets diagnostic systems for point-of-care and clinical laboratory segments, and has recently entered the wearable biosensor industry [4] Manufacturing and Regulatory Update - The approval from WHO allows Trinity Biotech to begin manufacturing its rapid HIV tests at the new offshore facility in Q1 2025, which is expected to enhance future growth and improve margins [2] - The transfer of manufacturing is part of the company's strategy to create shareholder value and demonstrates effective collaboration with global regulatory authorities [2]